Acumen Pharmaceuticals
ABOS
81 hedge funds and large institutions have $44.8M invested in Acumen Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 33 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
1% more funds holding
Funds holding: 80 → 81 (+1)
3.77% less ownership
Funds ownership: 70.79% → 67.03% (-3.8%)
33% less call options, than puts
Call options by funds: $45K | Put options by funds: $67K
39% less capital invested
Capital invested by funds: $73.2M → $44.8M (-$28.3M)
55% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pathstone Holdings
Englewood,
New Jersey
|
+$685K |
| 2 |
Invesco
Atlanta,
Georgia
|
+$154K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$78.6K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$74.1K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$59.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.16M |
| 2 |
Millennium Management
New York
|
-$299K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$188K |
| 4 |
Morgan Stanley
New York
|
-$162K |
| 5 |
JP Morgan Chase
New York
|
-$151K |
ABOS Hedge Fund Activity: Q1 2025 in Review
81 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2025, worth a combined $44.8M — down 39% from $73.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ABOS positions and 9 closed out — a net gain of 1 holder — while 15 added to existing stakes and 33 trimmed.
The largest buyer was Pathstone Holdings, adding an estimated $685K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $3.16M sold.
- 81 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2025, up from 80 in Q4 2024.
- Funds reported $44.8M of Acumen Pharmaceuticals stock for Q1 2025, down 39% quarter-over-quarter.
- 10 funds opened new Acumen Pharmaceuticals positions in Q1 2025 and 9 closed out, a net change of +1 holder.
- The largest Acumen Pharmaceuticals buyer in Q1 2025 was Pathstone Holdings, an estimated $685K added.
- The largest Acumen Pharmaceuticals seller in Q1 2025 was Rock Springs Capital Management, an estimated $3.16M sold.
Based on aggregated 13F filings for Q1 2025.